GDF3

1. Semaglutide is associated with GDF3 in humans (r = 0.437).

   Human trialin adults with visceral obesity12 weeksn = 23

   Serum GDF3 is Associated with Visceral Obesity, Insulin Resistance, and Inflammation in Non-Diabetic Adults: A Cross-Sectional Study with an Interventional Component

   Diabetes, metabolic syndrome and obesity : targets and therapy·13 Aug 2026

More on Semaglutide

1. GDF3 is associated with visceral obesity in humans (P < 0.001).

   Humansvisceral obesity vs without visceral obesityn = 282

   Serum GDF3 is Associated with Visceral Obesity, Insulin Resistance, and Inflammation in Non-Diabetic Adults: A Cross-Sectional Study with an Interventional Component

   Diabetes, metabolic syndrome and obesity : targets and therapy·13 Aug 2026

More on Visceral obesity